These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26356391)

  • 1. [Identification of people at the latent stage of Parkinson's disease (the PARKINLAR study): first results and an optimization of the algorithm].
    Fedotova EY; Chechetkin AO; Abramycheva NY; Chigaleychik LA; Baziyan BK; Ponomareva ТА; Alexeeva NS; Fedin PA; Kravchenko MA; Varakin YY; Ivanova-Smolenskaya IA; Illarioshkin SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(6):4-11. PubMed ID: 26356391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers.
    Vilas D; Ispierto L; Álvarez R; Pont-Sunyer C; Martí MJ; Valldeoriola F; Compta Y; de Fabregues O; Hernández-Vara J; Puente V; Calopa M; Jaumà S; Campdelacreu J; Aguilar M; Quílez P; Casquero P; Lomeña F; Ríos J; Tolosa E
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1170-6. PubMed ID: 26306001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease.
    Schweitzer KJ; Brüssel T; Leitner P; Krüger R; Bauer P; Woitalla D; Tomiuk J; Gasser T; Berg D
    J Neurol; 2007 May; 254(5):613-6. PubMed ID: 17415511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
    Brockmann K; Gröger A; Di Santo A; Liepelt I; Schulte C; Klose U; Maetzler W; Hauser AK; Hilker R; Gomez-Mancilla B; Berg D; Gasser T
    Mov Disord; 2011 Nov; 26(13):2335-42. PubMed ID: 21989859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fighting the risk of developing Parkinson's disease; clinical counseling for first degree relatives of patients with Parkinson's disease.
    Giladi N; Mirelman A; Thaler A; Bar-Shira A; Gurevich T; Orr-Urtreger A
    J Neurol Sci; 2011 Nov; 310(1-2):17-20. PubMed ID: 21704337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of combined midbrain sonography, olfactory and motor function assessment in the differential diagnosis of early Parkinson's disease.
    Busse K; Heilmann R; Kleinschmidt S; Abu-Mugheisib M; Höppner J; Wunderlich C; Gemende I; Kaulitz L; Wolters A; Benecke R; Walter U
    J Neurol Neurosurg Psychiatry; 2012 Apr; 83(4):441-7. PubMed ID: 22362921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
    Sierra M; Sánchez-Juan P; Martínez-Rodríguez MI; González-Aramburu I; García-Gorostiaga I; Quirce MR; Palacio E; Carril JM; Berciano J; Combarros O; Infante J
    Neurology; 2013 Feb; 80(7):621-6. PubMed ID: 23325906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants.
    Zhang L; Quadri M; Guedes LC; Coelho M; Valadas A; Mestre T; Lobo PP; Rosa MM; Simons E; Oostra BA; Ferreira JJ; Bonifati V
    Parkinsonism Relat Disord; 2013 Oct; 19(10):897-900. PubMed ID: 23726462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of combined assessment of olfaction and sustantia nigra hyperechogenicity for Parkinson's disease.
    López Hernández N; García Escrivá A; Shalabi Benavent M
    Neurologia; 2015 Oct; 30(8):496-501. PubMed ID: 24839905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-variance RNAs identify Parkinson's disease molecular signature in blood.
    Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC
    Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia.
    Mellick GD; Siebert GA; Funayama M; Buchanan DD; Li Y; Imamichi Y; Yoshino H; Silburn PA; Hattori N
    Parkinsonism Relat Disord; 2009 Feb; 15(2):105-9. PubMed ID: 18486522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
    Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
    Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.
    Gao L; Gómez-Garre P; Díaz-Corrales FJ; Carrillo F; Carballo M; Palomino A; Díaz-Martín J; Mejías R; Vime PJ; López-Barneo J; Mir P
    Eur J Neurol; 2009 Aug; 16(8):957-60. PubMed ID: 19473361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry.
    Pyatigorskaya N; Sharman M; Corvol JC; Valabregue R; Yahia-Cherif L; Poupon F; Cormier-Dequaire F; Siebner H; Klebe S; Vidailhet M; Brice A; Lehéricy S
    Mov Disord; 2015 Jul; 30(8):1077-84. PubMed ID: 26011561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant.
    Pchelina SN; Yakimovskii AF; Emelyanov AK; Ivanova ON; Schwarzman AL; Singleton AB
    Eur J Neurol; 2008 Jul; 15(7):692-6. PubMed ID: 18435766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.
    Tan EK; Skipper L; Chua E; Wong MC; Pavanni R; Bonnard C; Kolatkar P; Liu JJ
    Mov Disord; 2006 Jul; 21(7):997-1001. PubMed ID: 16602113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
    Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
    Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
    Zuo L; Motherwell MS
    Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subclinical signs in LRRK2 mutation carriers.
    Johansen KK; White LR; Farrer MJ; Aasly JO
    Parkinsonism Relat Disord; 2011 Aug; 17(7):528-32. PubMed ID: 21641848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.